The FDA ramps up action on compounded GLP‑1 weight‑loss drugs, targeting telehealth ads as Novo Nordisk sues Hims & Hers and regulators hint at seizures.
Brian J. Malkin, JD
Advertisement
Articles by Brian J. Malkin, JD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Medicare Is Finally Covering GLP-1s for Weight Loss: What the Bridge Program Means for Your Practice
2
Beyond Injections: The Rise of Oral GLP-1 Therapy
3
GLP-1 Reimbursement Crisis: What Independent Pharmacies Need to Know About Staying Viable
4
Automation in Pharmacy: Strategies for Health System Success
5